Nobel
Nobel İlaç is a privately held Turkish pharmaceutical manufacturer founded in 1964, producing generics, biosimilars, APIs and biotech drugs across five facilities in Turkey, Kazakhstan and Uzbekistan, and serving pharmacies, hospitals and government healthcare systems in 20 countries with owned organizations plus 50 export markets.
- Company typePrivate
- Founded1964
- HeadquartersTashkent, Uzbekistan
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nobel does
Nobel İlaç San. ve Tic. A.Ş. is a privately held Turkish pharmaceutical company founded in 1964 and wholly owned by Ulkar Holding, operating with 100% domestic Turkish capital. It manufactures and sells a broad portfolio of generic pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and biotechnological drug products, including Turkey's first biosimilar erythropoietin (launched 2010) and Tylol Hot, a flagship consumer cold/flu brand registered in 1998. The company runs five manufacturing facilities — Düzce (main facility, ~40,000 m² closed area), Gebze MARTEK (biotechnology, 2x1000L reactor capacity), Çerkezköy/Ulkar Kimya (APIs and coated micropellets) in Turkey, plus Nobel AFF in Almaty, Kazakhstan and Nobel Pharmsanoat in Tashkent, Uzbekistan — together producing over 360 SKUs across roughly 143 molecules, with annual capacity of 750 million tablets at Nobel AFF and 10 million boxes at Pharmsanoat. Approximately 3,000 employees support operations across 20 countries with owned direct-sales organizations and exports to roughly 50 countries.
The business model is primarily horizontal generic-pharma sales into government healthcare systems, hospital networks and retail pharmacies across CIS, Balkans, Central Asia, Caucasus and select European markets, supported by owned distribution rather than third-party channels. R&D is conducted at three centers (Düzce Pharmaceutical R&D, MARTEK Biotechnology, Ulkar Kimya), with 95% of the Turkish product portfolio developed in-house. Notable technical milestones include the first Turkish-EU-GMP certifications (2009), the first biosimilar erythropoietin launch in Turkey (2010), and the KAMAG-1007 BIOSIM-1 state-supported biosimilar program (2015, $10M TÜBİTAK support) plus an original biotechnological molecule development partnership with Bilkent University (2016). Capital deployment includes $40M (2002) and $30M (2015) into Nobel AFF, with a further $50M planned for biotech, and $25M from IFC (2017) for the biotechnology facility — alongside TÜBİTAK and TURQUALITY program support. Pricing is not publicly disclosed; the company monetizes through direct B2B sales to pharmacies, hospitals and government procurement channels rather than digital or consumer-direct channels.
Nobel firmographics
Firmographics- Name
- Nobel
- Legal name
- Nobel İlaç Sanayi ve Ticaret Anonim Şirketi (A.Ş.)
- Website
- https://nobel.uz
- Company type
- Private
- Founded year
- 1964
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nobel İlaç is a privately held Turkish pharmaceutical manufacturer founded in 1964, producing generics, biosimilars, APIs and biotech drugs across five facilities in Turkey, Kazakhstan and Uzbekistan, and serving pharmacies, hospitals and government healthcare systems in 20 countries with owned organizations plus 50 export markets.
- Ownership category
- akta.pro rank
Nobel industry classification
Industry- Product category
- Generic Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)
Keywords
Where Nobel is headquartered
LocationHeadquarters
- HQ city
- Tashkent
- HQ country
- Uzbekistan
- HQ region
- Asia
Offices8 records
Markets served
Nobel business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Nobel generates revenue through manufacturing and selling pharmaceutical products including drugs, supplements, and medical products. The company exports to 50 countries and conducts direct sales through own organizations in 20 countries.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Nobel product offering
Product offeringCore offering
Nobel manufactures and sells a broad portfolio of generic pharmaceutical drug products, biotechnological drugs (including biosimilars such as erythropoietin), active pharmaceutical ingredients, and coated micropellets. Its products are distributed to pharmacies, hospitals, and healthcare providers across roughly 50 export countries, with the company operating its own sales organizations in 20 countries and five manufacturing facilities in Turkey, Kazakhstan, and Uzbekistan.
Product overview
Nobel is a Turkish pharmaceutical company founded in 1964 with 100% domestic capital, operating globally with 5 manufacturing facilities (3 in Turkey, 1 in Kazakhstan, 1 in Uzbekistan) and own organizations in 20 countries. The company produces a comprehensive portfolio of generic pharmaceutical products including Albebezol (albendazole), Aldobel (sildenafil), Alzanser (olanzapine), Anzibel (chlorhexidine lozenges), Antagrix (clopidogrel), Aprid (amoxicillin/clavulanic acid), Afil (alfuzosin), Tylol Hot, and Neotylol for cold/flu treatment. Nobel exports to approximately 50 countries. Their manufacturing operations include Nobel Pharmsanoat in Uzbekistan (10 million boxes/year capacity, 110 products), Nobel AFF in Kazakhstan (750 million tablets/year, 250 products), Gebze MARTEK for biotechnological drugs (2x1000L reactors), Düzce Manufacturing Facility for conventional dosage forms, and Ulkar Kimya for active pharmaceutical ingredients. Nobel also publishes Nobel Medicus, a peer-reviewed medical journal.
Differentiator
Problem solved
Functional benefit
Brands
- Nobel Pharma Schweiz AG: Subsidiary handling pharmaceutical operations in Switzerland
- Generinobel
- Nobelfarma
- Plantafarma
- Nobel Medicus
Products and services
- Tylol Hot
Quantifiable outcome
- First biosimilar erythropoietin product launched in Turkey (2010)
- +2 more outcomes
Companies that use Nobel
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles3 records
Nobel technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nobel partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Bilkent UniversitycorePartnership with Bilkent University for recombinant bi-mAb project - Turkey's first biotechnological original molecule development project, started in 2016 with TÜBİTAK support.
- Institute of Herbal Substances Chemistry of Uzbekistan Academy of SciencesminorNobel Pharmsanoat cooperates with the Institute for development of pharmaceutical products based on local officinal plants of Uzbekistan. 3 of 5 products manufactured with domestic active substances are exported abroad.
- Ulkar HoldingcoreNobel Pharmaceuticals is part of Ulkar Holding. Ulkar Holding encompasses Nobel İlaç and other companies including Ulkar Kimya. Nobel AFF and Nobel Pharmsanoat are subsidiaries under Ulkar Holding.
- Turkish Ministry of HealthcoreUlkar Kimya holds EU GMP certificate awarded by Turkish Republic Ministry of Health (PIC member) as well as BfArM Germany certification.
- TURQUALITY ProgramcoreNobel Pharmaceuticals was included in the brand support program (TURQUALITY) within the framework of the state-supported branding program in 2014.
Scale indicators10 records
Recent moves14 records
Expansion highlights5 records
Nobel competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma: Indian generic pharmaceutical manufacturer with global distribution and growing biosimilar portfolio. Comparable in combining generic manufacturing scale with international expansion into emerging markets, including CIS regions where Nobel also operates.
- Dr. Reddy's Laboratories: Indian generic and biosimilar manufacturer with significant emerging-markets footprint and growing biosimilar pipeline. Comparable to Nobel in combining generic production with biosimilar capabilities, though at much larger scale.
- KRKA: Slovenian generic pharmaceutical manufacturer with strong CIS, Central/Eastern European, and Russian market presence. Similar size and international expansion strategy to Nobel, with comparable generic-portfolio and own-distribution approach.
- Eczacıbaşı Pharmaceuticals: Turkish conglomerate-affiliated pharmaceutical manufacturer, also part of a diversified holding group (similar to Nobel's Ulkar Holding structure). Competes with Nobel in Turkey and selected international markets with generic and branded pharmaceutical products.
- Stada Arzneimittel: European-focused generic pharmaceutical company with strong presence in CIS and Eastern European markets - highly comparable to Nobel's geographic focus. Both emphasize biosimilar/generic portfolios with multi-country own-distribution models.
- Hikma Pharmaceuticals: Jordan-headquartered generic pharmaceutical company with strong MENA and emerging-markets presence. Comparable business model to Nobel's own-distribution approach across multiple geographies, with similar product portfolio breadth.
- Abdi İbrahim: Turkey's largest pharmaceutical company and direct domestic peer. Both are Turkish-headquartered generic pharmaceutical manufacturers with international operations and own distribution organizations across multiple countries, competing head-to-head in CIS, European, and emerging markets.
Broad incumbents
- Sandoz: Global leader in generic pharmaceuticals and biosimilars (Novartis spin-off). Competes with Nobel in generics and biosimilars globally; much larger scale and broader geographic footprint make Sandoz a broad incumbent rather than a direct niche competitor.
- Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive biosimilar pipeline. Competes with Nobel in global generics and biosimilars but operates at vastly larger scale and broader geographic scope as a broad incumbent.
Regional players
- Polpharma: Poland's largest pharmaceutical manufacturer with focus on generics, APIs, and biosimilars. Comparable vertically-integrated model (own API production) and Central/Eastern European market focus, though primarily Poland-centric rather than Turkey-based.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Nobel social profiles
Digital presenceNobel compliance and trust
Trust signalCompliance13 records
Nobel financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nobel leadership team
Management profileNumber of profiles
Profiles4 records
Nobel subsidiaries and ownership
Company hierarchySubsidiaries9 records
Nobel funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nobel M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nobel
What does Nobel do?
Nobel manufactures and sells a broad portfolio of generic pharmaceutical drug products, biotechnological drugs (including biosimilars such as erythropoietin), active pharmaceutical ingredients, and coated micropellets. Its products are distributed to pharmacies, hospitals, and healthcare providers across roughly 50 export countries, with the company operating its own sales organizations in 20 countries and five manufacturing facilities in Turkey, Kazakhstan, and Uzbekistan.
Is Nobel a public or private company?
Nobel is a private company. It is classified as corporate owned and is currently operating.
When was Nobel founded?
Nobel was founded in 1964. It employs 11 to 50 people.
Where is Nobel based?
Nobel is headquartered in Tashkent, Uzbekistan, in the Asia region.
How does Nobel make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Nobel's main competitors?
Direct peers on record are Aurobindo Pharma, Dr. Reddy's Laboratories, KRKA, Eczacıbaşı Pharmaceuticals, Stada Arzneimittel, Hikma Pharmaceuticals and Abdi İbrahim. Broad incumbents are Sandoz and Teva Pharmaceutical Industries. Polpharma is listed as a regional player.
Does Nobel have an API?
No public API is recorded for Nobel.
What industry is Nobel in?
Nobel's product category is Generic Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 325412 and its SIC code is 2834.